Charles River Laboratories International, Inc. logo
Charles River Laboratories International, Inc. (CRL)
Compare

Charles River Laboratories International, Inc. (CRL) EV/FCF Ratio: 30.84x

Is Charles River Laboratories International, Inc.’s EV/FCF ratio high or low?

Charles River Laboratories International, Inc.'s EV/FCF ratio of 30.84x is 12% below its 5-year average of 35.23x, around the middle of its 5-year range (15.21x–58.96x).

The EV/FCF ratio for Charles River Laboratories International, Inc. (CRL) is 30.84x as of Wednesday, June 10, 2026. It is above its 12-month average by 45.23% (21.24x).

CRL EV/FCF Ratio Chart

CRL EV/FCF Ratio
30.84x+66.43% 1Y
Zoom

CRL Average EV/FCF Ratio Chart

CRL Current vs Average EV/FCF Ratio Chart

CRL EV/FCF Ratio Metrics

EV/FCF RATIO

30.84x

EV/FCF RATIO AVG TTM

21.24x

EV/FCF RATIO AVG 3Y

29.09x

EV/FCF RATIO AVG 5Y

35.23x

EV/FCF RATIO AVG 10Y

31.58x

EV/FCF RATIO AVG 15Y

27.18x

EV/FCF RATIO AVG 20Y

42.67x

CURRENT VS TTM AVG

+45.23%

CURRENT VS 3Y AVG

+6.03%

CURRENT VS 5Y AVG

-12.46%

CURRENT VS 10Y AVG

-2.34%

CURRENT VS 15Y AVG

+13.48%

CURRENT VS 20Y AVG

-27.72%

CRL Competitors' EV/FCF Ratio

NAMEMARKET CAPEV/FCF RATIOTTM3Y5Y
Charles River Laboratories International, Inc. (CRL)$9.06B30.84x21.24x29.09x35.23x
Bio-Rad Laboratories, Inc. (BIO)$7.89B24.48x25.09x43.47x51.10x
Baxter International Inc. (BAX)$10.49B25.39x68.29x51.70x47.33x
Hims & Hers Health, Inc. (HIMS)$6.42B98.69x83.00x71.55x71.55x
Align Technology, Inc. (ALGN)$12.56B16.92x17.72x29.59x38.96x
Hologic, Inc. (HOLX)$16.97B17.53x16.89x18.61x15.13x
Moderna, Inc. (MRNA)$18.40BN/A26.90x26.23x26.23x
BioNTech SE (BNTX)$21.81B7.13x22.05x6.21x11.27x
Mettler-Toledo International Inc. (MTD)$22.85B31.65x33.77x33.51x38.38x
Waters Corporation (WAT)$23.83B133.18x43.36x43.04x41.43x

Cash Flow Valuation Comparison

EV/FCF

30.8x

P/FCF

23.5x

FCF Yield

4.25%

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

  • EV/FCF accounts for debt and cash through enterprise value
  • P/FCF only considers equity value
  • EV/FCF can be compared across companies with different debt levels
  • Both measure how the market values cash generation

Charles River Laboratories International, Inc. EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Charles River Laboratories International, Inc. EV/FCF Ratio FAQ

What is the EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The EV/FCF ratio for CRL stock is 30.84x.
Is Charles River Laboratories International, Inc.'s EV/FCF ratio high or low?
Charles River Laboratories International, Inc.'s EV/FCF ratio of 30.84x is 12% below its 5-year average of 35.23x, around the middle of its 5-year range (15.21x–58.96x).
What is the TTM average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The TTM average EV/FCF ratio for CRL stock is 21.24x.
What is the 3Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The 3Y average EV/FCF ratio for CRL stock is 29.09x.
What is the 5Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The 5Y average EV/FCF ratio for CRL stock is 35.23x.
What is the 10Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The 10Y average EV/FCF ratio for CRL stock is 31.58x.
What is the 15Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The 15Y average EV/FCF ratio for CRL stock is 27.18x.
What is the 20Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
The 20Y average EV/FCF ratio for CRL stock is 42.67x.

Charles River Laboratories International, Inc. EV/FCF Ratio History

DATEEV/FCF RATIO
2026-06-1030.84x
2026-06-0931.07x
2026-06-0830.64x
2026-06-0530.01x
2026-06-0430.56x
2026-06-0329.82x
2026-06-0229.19x
2026-06-0130.10x
2026-05-2929.93x
2026-05-2830.01x
2026-05-2727.90x
2026-05-2626.93x
2026-05-2227.37x
2026-05-2127.19x
2026-05-2026.84x
2026-05-1926.39x
2026-05-1826.08x
2026-05-1526.19x
2026-05-1427.23x
2026-05-1327.69x
2026-05-1228.42x
2026-05-1128.40x
2026-05-0829.54x
2026-05-0730.05x
2026-05-0622.75x
2026-05-0523.10x
2026-05-0421.86x
2026-05-0121.24x
2026-04-3021.35x
2026-04-2921.05x
2026-04-2821.33x
2026-04-2721.75x
2026-04-2421.62x
2026-04-2321.42x
2026-04-2223.04x
2026-04-2122.88x
2026-04-2023.11x
2026-04-1722.95x
2026-04-1622.30x
2026-04-1522.64x
2026-04-1422.52x
2026-04-1322.43x
2026-04-1022.17x
2026-04-0922.16x
2026-04-0822.12x
2026-04-0721.59x
2026-04-0621.47x
2026-04-0222.01x
2026-04-0122.10x
2026-03-3121.87x
2026-03-3020.66x
2026-03-2720.61x
2026-03-2621.17x
2026-03-2521.25x
2026-03-2420.61x
2026-03-2320.50x
2026-03-2020.08x
2026-03-1920.03x
2026-03-1820.41x
2026-03-1720.09x
2026-03-1619.93x
2026-03-1320.26x
2026-03-1219.99x
2026-03-1121.53x
2026-03-1021.39x
2026-03-0922.30x
2026-03-0622.06x
2026-03-0522.71x
2026-03-0422.55x
2026-03-0322.18x
2026-03-0222.45x
2026-02-2722.44x
2026-02-2622.15x
2026-02-2521.41x
2026-02-2421.26x
2026-02-2321.02x
2026-02-2021.53x
2026-02-1921.09x
2026-02-1820.50x
2026-02-1718.87x
2026-02-1319.13x
2026-02-1218.89x
2026-02-1119.55x
2026-02-1020.93x
2026-02-0921.34x
2026-02-0621.66x
2026-02-0521.16x
2026-02-0422.79x
2026-02-0322.77x
2026-02-0223.84x
2026-01-3023.59x
2026-01-2923.70x
2026-01-2824.17x
2026-01-2724.42x
2026-01-2624.67x
2026-01-2324.42x
2026-01-2224.82x
2026-01-2125.07x
2026-01-2024.29x
2026-01-1624.43x
2026-01-1524.77x
2026-01-1424.13x
2026-01-1324.37x
2026-01-1224.35x
2026-01-0924.54x
2026-01-0824.05x
2026-01-0724.16x
2026-01-0624.10x
2026-01-0523.40x
2026-01-0222.86x
2025-12-3122.59x
2025-12-3022.82x
2025-12-2922.93x
2025-12-2622.97x
2025-12-2422.93x
2025-12-2322.90x
2025-12-2222.91x
2025-12-1922.37x
2025-12-1822.08x
2025-12-1722.27x
2025-12-1622.21x
2025-12-1522.47x
2025-12-1222.01x
2025-12-1122.13x
2025-12-1022.17x
2025-12-0921.37x
2025-12-0821.47x
2025-12-0521.21x
2025-12-0421.19x
2025-12-0321.25x
2025-12-0220.35x
2025-12-0120.47x
2025-11-2820.65x
2025-11-2620.73x
2025-11-2520.64x
2025-11-2419.95x
2025-11-2119.70x
2025-11-2019.19x
2025-11-1919.15x
2025-11-1819.23x
2025-11-1719.25x
2025-11-1419.71x
2025-11-1319.84x
2025-11-1220.05x
2025-11-1120.23x
2025-11-1019.82x
2025-11-0719.74x
2025-11-0619.99x
2025-11-0519.70x
2025-11-0419.66x
2025-11-0319.75x
2025-10-3119.85x
2025-10-3019.77x
2025-10-2919.86x
2025-10-2820.52x
2025-10-2721.15x
2025-10-2421.30x
2025-10-2320.78x
2025-10-2220.44x
2025-10-2120.55x
2025-10-2020.20x
2025-10-1719.72x
2025-10-1619.41x
2025-10-1519.05x
2025-10-1419.00x
2025-10-1319.05x
2025-10-1018.74x
2025-10-0919.17x
2025-10-0819.29x
2025-10-0719.00x
2025-10-0619.41x
2025-10-0319.62x
2025-10-0219.45x
2025-10-0119.03x
2025-09-3017.84x
2025-09-2917.03x
2025-09-2617.16x
2025-09-2516.91x
2025-09-2417.24x
2025-09-2317.31x
2025-09-2217.62x
2025-09-1917.75x
2025-09-1817.88x
2025-09-1717.52x
2025-09-1617.42x
2025-09-1517.48x
2025-09-1217.53x
2025-09-1118.12x
2025-09-1017.57x
2025-09-0917.92x
2025-09-0818.31x
2025-09-0518.48x
2025-09-0418.34x
2025-09-0318.34x
2025-09-0218.25x
2025-08-2918.42x
2025-08-2818.41x
2025-08-2718.38x
2025-08-2618.46x
2025-08-2518.49x
2025-08-2218.30x
2025-08-2117.67x
2025-08-2018.10x
2025-08-1918.01x
2025-08-1817.88x
2025-08-1517.86x
2025-08-1417.78x
2025-08-1317.71x
2025-08-1217.52x
2025-08-1117.20x
2025-08-0817.18x
2025-08-0717.27x
2025-08-0617.32x
2025-08-0520.02x
2025-08-0420.05x
2025-08-0119.96x
2025-07-3120.21x
2025-07-3020.80x
2025-07-2921.01x
2025-07-2821.05x
2025-07-2520.87x
2025-07-2420.88x
2025-07-2320.06x
2025-07-2219.64x
2025-07-2118.42x
2025-07-1818.84x
2025-07-1719.04x
2025-07-1618.88x
2025-07-1518.84x
2025-07-1419.16x
2025-07-1119.29x
2025-07-1019.67x
2025-07-0919.25x
2025-07-0819.19x
2025-07-0718.79x
2025-07-0319.08x
2025-07-0219.11x
2025-07-0118.83x
2025-06-3018.59x
2025-06-2718.44x
2025-06-2618.58x
2025-06-2518.46x
2025-06-2418.29x
2025-06-2318.20x
2025-06-2018.21x
2025-06-1818.01x
2025-06-1717.99x
2025-06-1618.53x
2025-06-1318.39x
2025-06-1218.61x
2025-06-1118.54x
2025-06-1018.53x
2025-06-0918.21x
2025-06-0617.96x
2025-06-0517.64x
2025-06-0417.82x
2025-06-0317.40x
2025-06-0217.09x
2025-05-3017.14x
2025-05-2917.33x

Showing the most recent 260 of 4,916 data points. The chart above shows the full history.

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA
18,700 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James C. Foster